Spencer Berthelsen Sells Ionis Pharmaceuticals Shares

On June 15, 2026, Spencer Berthelsen sold 8,000 shares of Ionis Pharmaceuticals, Inc. (NasdaqGS: IONS). The transaction was not part of a pre-planned arrangement, and the shares were sold at an unspecified price. At the time, Ionis Pharmaceuticals was trading at $73.96.

Insider Buying and Selling at Ionis Pharmaceuticals, Inc.

Spencer Berthelsen was involved in multiple transactions on June 15, 2026, including a non-planned sale of 8,000 shares. Holly Kordasiewicz, Executive Vice President and Chief Development Officer, also executed sales of 60,846 shares on June 12, 2026, with some transactions being planned.

Other Institutional Activity in Ionis Pharmaceuticals

Several institutional investors have recently adjusted their holdings in Ionis Pharmaceuticals. FMR LLC increased its position by 484,536 shares, now holding 24,556,637 shares valued at about $1.84 billion. CAPITAL WORLD INVESTORS boosted its stake by 3,225,070 shares, bringing its total to 21,186,369 shares worth approximately $1.59 billion. On the other hand, BLACKROCK, INC. reduced its holdings by 205,387 shares, ending with 10,442,476 shares valued at $784.1 million.

Ionis Pharmaceuticals, Inc. Stock Up 19.7%

Ionis Pharmaceuticals is currently trading near $73.96, with a market capitalization of $12.22 billion. The company, focused on RNA-targeted medicines, has a forward P/E ratio that is not meaningful due to its lack of profitability. The stock has a 52-week low of $34.84 and a high of $86.74, with a 50-day moving average of $74.93 and a 200-day moving average of $74.61. The company maintains a strong current ratio of 4.10, though it carries a high debt-to-equity ratio of 531.05.

Recent Earnings

In its most recent financial results, Ionis Pharmaceuticals reported revenue of $1.06 billion, reflecting a growth rate of 0.87%. However, the company posted a net margin of -30.9% and a return on equity of -67.6%, indicating significant financial challenges. The next earnings report is anticipated on August 5, 2026.

Analysts Set New Price Targets

Analysts have been active in setting new price targets for Ionis Pharmaceuticals. On May 19, 2026, Citigroup initiated coverage with a 'buy' rating and a target price of $115. RBC Capital, Barclays, and HC Wainwright & Co. all maintained their 'buy' ratings with target prices of $100, $115, and $125, respectively. The consensus among analysts is a 'buy' recommendation, with an average target price of $102.17 based on 24 opinions.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, headquartered in Carlsbad, California, is a biotechnology company that develops RNA-targeted medicines. The company offers treatments for conditions like familial chylomicronemia syndrome, hereditary angioedema, and spinal muscular atrophy. Ionis is also advancing a pipeline of products in various stages of clinical trials. The company collaborates with major pharmaceutical firms including Biogen, GSK, and AstraZeneca.

Bottom Line

Spencer Berthelsen's recent sale of Ionis Pharmaceuticals shares is a noteworthy event for investors tracking insider activity. The company, with its focus on RNA-targeted therapies, continues to draw significant attention from institutional investors and analysts. While the stock's forward P/E ratio is not meaningful due to ongoing losses, its robust pipeline and strategic partnerships offer potential for future growth.